News

VABYSMO is the first treatment for wet AMD and DME in Canada that acts by targeting both VEGF-A and Ang-2, two key drivers of vascular instability that have been associated with vision-threatening retinal conditions.

Results of the study, published in the Journal of Clinical Investigation, showed evidence that an experimental drug called 32-134D may prevent or slow vision loss in people with diabetes.

The day helps to bring focus and awareness to risk factors for early vision loss associated with smoking.

According to the company, the Preservative Freedom Coalition will put the topic of preservative-free eye care in focus through education to eye care professionals and patients.

Oxurion NV has reached its enrollment target of 108 patients in its KALAHARI Phase 2, Part B clinical trial for diabetic macular edema (DME) and will likely continue to include additional participants in the trial due to high interest.

The photochromic lenses, available in Singapore, provide added protection against intensive sunlight and can darken outdoors and fade back to transparent indoors.

New option a potential treatment for patients diagnosed with dry eye disease.

Early detection and diagnosis are key for these young patients

Alimera Sciences, Inc. has completed enrollment for its NEW DAY clinical trial (NCT04469595). Participants are patients diagnosed with diabetic macular edema (DME).

Data supports ANX007 as the first complement therapy to preserve visual acuity, achieving statistically significant protection, but reduction in rate of geographic atrophy lesion growth did not reach statistical significance.

The research conducted at the Wayne State University School of Medicine implies that VCAM1 antagonism could be a promising therapeutic strategy for proliferative retinal disorders.

Dual therapy may slow the progression of condition.

Accessibility obstacles could prevent those with sight loss from receiving support and care.

Curative Biotechnology Inc. has completed and filed a patent cooperation treaty (PCT) application with the U.S. Receiving Office.

The iPredict AI Eye Screening System will provide a fully automated age-related macular degeneration (AMD) screening report in less than 60 seconds.

The company is currently developing treatments for age related macular degeneration as injections and eye drops, among others.

According to the company, its latest laser recently received FDA clearance and CE mark approval.

According to the company, THR-149 is currently being evaluated in the KALAHARI Phase 2, Part B clinical trial as a potential treatment for patients who respond suboptimally to anti-VEGF, the standard of care for treatment of DME.

Data supports ANX007 as the first complement therapy to preserve visual acuity, achieving statistically significant protection, but reduction in rate of geographic atrophy lesion growth did not reach statistical significance.

Medical, surgical management can be important tools.

While the 6-weekly regimen was less effective in improving the clinical activity score or exophthalmos than the higher dose regimen, it is an acceptable treatment choice for patients with marginal or lower clinical activity scores.

What ophthalmologists want patients to know ahead of UK bank holiday.

The project, a collaboration with researchers from the University of Maryland, holds promise for advancing new and more tolerable drug treatments for common chronic blinding eye diseases, including glaucoma and macular degeneration.

According to the company, AG-73305 was found to be safe and tolerable with no severe adverse effects after a single intravitreal injection of 0.5 mg and 1 mg in patients diagnosed with diabetic macular edema.

Allgenesis announces preliminary data for its on-going trial and anticipates the release of the final topline data in 4Q23.

According to the company, topical administration is capable of delivering metformin to choroid, RPE, and retina.

SLT shows promise as treatment for millions of Africans with glaucoma.

Louis R. Pasquale, MD, FARVO, will be presented the award by previous winner Robert N. Weinreb, MD.